interview
investors
Interview: Cayman Chemical validates eXoZymes'...
Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter...
investors
Rapid Scale-Up: Enzyme Breakthrough Achieved! (01)
One of the biggest challenges of conventional technologies is the long timelines to advance...
interview
The Catalyst Podcast: Interview with CEO...
The Catalyst Podcast by Igor Rafalovich is available here:...
interview
Inside Biotech podcast (E34): Michael Heltzen...
Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is...
interview
The challenges of SynBio - by Zachary Karl, PhD
“Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a...
investors
NCT: Damien on 4 grams of NCT with over 99%...
🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a...
investors
NCT: From concept to gram-scale quantity in...
🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone...
interview
Slack Capital interview: Chris Marlett,...
Last week, Slack Capital - an Australian investment research publication - released an investment...
interview
Slack Capital interview: Chris Marlett,...
Last week, Slack Capital - an Australian investment research publication - released an investment...
investors
Slack Capital interview: Damien Perriman, CCO
Last week, Slack Capital - an Australian investment research publication - has released an...